RAIN - Rain Oncology Goes Private Just Two Years After $120M NASDAQ Debut | Benzinga
Rain Oncology Inc (NASDAQ: RAIN) has agreed to be acquired by Pathos AI Inc. for $1.16 in cash per share plus a non-tradeable contingent value right (CVR) for potential cash payments of up to approximately $0.17 per share.
The upfront cash consideration represents a 17% premium over Rain's unaffected stock price as of October 13, 2023.
"After a thorough assessment, the Rain Board determined that this Transaction is in the best interests of our stockholders, as it leverages Rain's strong cash position to provide a confirmed cash ...